Commentary

Microchimerism, macrochimerism, and tolerance

This work was supported by the National Institutes of Health grants DK 29961, ROI AI038899, and ROI DK 54232.

The meta-analysis of Sahota et al. (1) suggests that donor leukocyte microchimerism in organ recipients is a 'real finding' that varies with the organ transplanted and the time of post-operative sampling, and is detectable with the appropriate technology from center to center. The meta-analysis also reflects the lack of consensus about the significance of microchimerism. This uncertainty has been perpetuated in part by incorrectly attributing to us the opinion that microchimerism implies freedom from risk of rejection and or that its presence or level can be used to guide drug weaning. Sahota et al. (1) have avoided these errors. Nevertheless, inaccurate citations to this effect (1) have been used secondarily to support the contention that the mechanisms of organ engraftment are different than those of bone marrow-induced tolerance (3-5).

The clinical field of organ transplantation is based on the fact that a host response against the graft, which may or may not be strong enough to cause clinical or histopathologic findings of rejection, is readily reversible and often is succeeded by a decline in the antigraft reactivity that is reflected by a reduced need for immunosuppression (6).

The alteration in the host–graft relationship implied by these observations remained unknown until it was discovered in patients with long-surviving organ allografts that bone marrow-derived 'passenger leukocytes' migrated from the allografts to ubiquitous host locations and persisted for as long as three subsequent decades (7, 8).

From these findings, we deduced that the chimerism-associated mechanisms of organ engraftment involved a double-immune reaction (Fig. 1) and were the same in principle as those leading to tolerance following bone marrow transplantation to cytoablated recipients (7-9). Furthermore, it was emphasized that chimerism, whether at a 'micro' or 'macro' level was only a necessary condition for, but was not synonymous with, either allograft acceptance or tolerance. This concept has been strengthened by a series of experimental studies (10-13) and has readily accommodated and explained observations made by its critics (14, 15).

The host-versus-graft (HVG) reaction after either kind of transplantation is analogous to the adaptive immune response to intracellular noncytopathic microorganisms (16-19) (Fig. 2). However, the consequences are more complex than those of a host versus pathogen response because of the countervailing graft-versus-host (GVH) reaction mounted by mobile immunocompetent 'passenger leukocytes' of the allograft (Fig. 1). We have proposed that the HVG and GVH immune reactions are regulated after both organ and conventional bone marrow transplantation by the migration and localization of the respective immunogenic leukocytes (19).

To induce an effective response, the antigen must be delivered to organized lymphoid collections that are epitomized by, but not limited to, the lymphoid organs (18, 19). In this milieu, factors are present in abundance that are necessary for efficient immune activation (e.g. cytokines, other molecules, cell to cell proximity) (18). After transplantation, the donor 'passenger leukocytes' leave
the allograft, and migrate preferentially to the recipient lymphoid organs (20–22). If an antigen primarily bypasses or secondarily avoids organized lymphoid collections, the immune system may remain or become ‘indifferent’ to its presence (17–19).

In addition to governing the initiation of the double-immune response, antigen migration and localization regulate the termination of the dual response (19). It is well known that the GVH reaction usually is the stronger one in the cytoablative bone marrow recipient, whereas the dominant response in the organ recipient is usually HVG. If either immunocyte population completely rejects the other, the IL2 production of the surviving leukocyte cohort ceases and its antigen-specific clonal expansion is terminated by apoptosis. This ‘antigen withdrawal’ apoptosis requires new protein synthesis, is strongly inhibited by Bc1-2 and related anti-apoptotic molecules, and is thought to involve mitochondrial apoptosis mechanisms rather than the death cytokines such as Fas ligand (FasL) and tumor necrosis factor (TNF) [summarized in (23)].

Alternatively, persistence of the dual sources of antigen may drive the double-immune reaction to mutual clonal exhaustion-deletion (7, 8, 19), involving different molecular pathways of apoptosis including FasL and TNF (23). The consequence of this kind of apoptosis may be reciprocal antigen-specific clonal exhaustion-deletion (24–26). Although the exhaustion-deletion is probably never absolute, it is thought to be maintained after successful transplantation in a dynamic but potentially stable state by the periodic 'leakage' of leukocytes from non-lymphoid to lymphoid areas (18, 19), as has been described in an experimental model of diabetes (27). In tissue and organ recipients, the mobile antigen (i.e. the donor leukocyte microchimerism) rather than the 'fixed' parenchymal cells of a graft is essential for the maintenance of tolerance (13). If the MHC-restricted HVG reaction to a transplanted organ is not terminated either by the induction of donor-specific tolerance (Fig. 2A), or by rejection of the allograft (Fig. 2B), the response becomes unrelenting and results in chronic rejection (Fig. 2C).

Discovery of the linkage between hematolymphopoietic chimerism and organ transplantation prompted the development of a paradigm that has challenged multiple dogmas of transplantation and general immunology, while explaining previously enigmatic observations in clinical transplantation (7–9, 15, 19). At a basic level, it has been possible for the first time to define precisely the meaning of ‘transplantation tolerance’ and the mechanisms by which it is achieved (i.e. clonal exhaustion-deletion and immune indifference) (19). In a therapeutic context, it is obvious why it has been so difficult in HLA mismatched human organ recipients to achieve the closely related objectives of drug-free tolerance and freedom from chronic rejection.

In order to avoid losing allografts to acute rejection, intense immunosuppression is administered during the first few post-operative weeks of the acute donor-specific clonal expansion set in motion by the migration into the host of immunostimulatory donor passenger leukocytes. Because donor-specific clonal exhaustion-deletion is dependent on the acute clonal activation, the early post-transplantation period provides the prime window of opportunity for tolerance induction (7, 8). While saving the graft from rejection, the penalty for eroding the seminal mechanism of tolerogenesis with heavy immunosuppression may be the inability to ever stop drug treatment. Under these circumstances, chronic rejection supervenes if the maintenance doses are reduced below the critical threshold necessary to compensate for the incompleteness of the original tolerance induction.
When it was recognized that the donor passenger leukocytes of bone marrow origin were responsible for organ-induced tolerance, efforts began in earnest to augment the natural process by the infusion of adjacent donor bone marrow cells (28) as had long been advocated empirically by Monaco et al. (29). However, because this has required the same fundamentally anti-tolerogenic immunosuppression as for conventional organ transplantation, the results have been disappointing as is apparent from the meta-analysis of Sahota et al (1). The low-level chimerism normally found in organ recipients has been increased manifold (28, 30, 31), and has been reported in some studies to correlate with a higher incidence of donor-specific non-reactivity. However, discontinuation of immunosuppression has not been achieved.

Finding the optimal zone between under-treatment (with consequent destructive immunity) and over-treatment (with excessive erosion of tolerance) is the channel between Scylla and Charybdis that is being sought by workers in transplantation. The task has been made more daunting by the fact that the appropriate conditions, unlike those in inbred animal tolerance models, are never exactly the same in any two human recipients. It is possible that clonal exhaustion-deletion can be accomplished more efficiently with new agents such as the monoclonal antibodies that block co-stimulation and therefore prevent clonal expansion at a very early stage (32–34). However, the basic requirement for, and mechanisms of, acquired tolerance will remain the same.

Thomas E Starzl
Noriko Murase

References


Correspondence:
Thomas Starzl
Department of Surgery
University of Pittsburgh
PA 15213
USA